Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Journal for Immunotherapy of Cancer
Paolo A AsciertoIgor Puzanov

Abstract

Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.

References

May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa H ButterfieldJames S Economou
Nov 5, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Daniel H PalmerDavid H Adams
Oct 29, 2010·Science Translational Medicine·Chrystal M PaulosCarl H June
Nov 16, 2010·Seminars in Oncology·Shawn M JensenBernard A Fox
May 12, 2011·Cellular and Molecular Life Sciences : CMLS·Bence GyörgyEdit I Buzás
Jul 19, 2011·Hematology/oncology Clinics of North America·Jacalyn Rosenblatt, David F McDermott
Aug 4, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher G TwittyBernard A Fox
Jun 8, 2012·Science Translational Medicine·Sharanya SivanandJames Brugarolas
Jun 12, 2012·Nature Genetics·Samuel Peña-LlopisJames Brugarolas
Aug 14, 2012·Journal of Cancer Research and Clinical Oncology·Mervat El AnsaryOlfat Abdelhalim
Oct 24, 2012·Journal of Immunotherapy·Christopher A KlebanoffNicholas P Restifo
Jul 11, 2014·Nature Protocols·Andrea Pavía-JiménezJames Brugarolas
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Apr 14, 2015·The Journal of Clinical Investigation·Joe-Marc ChauvinHassane M Zarour
Sep 16, 2015·Nature Reviews. Neurology·Manfred Westphal, Katrin Lamszus
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Nov 13, 2015·British Journal of Haematology·Shannon Maude, David M Barrett
Dec 15, 2015·The Journal of Clinical Investigation·Christopher A KlebanoffNicholas P Restifo
Jan 7, 2016·Nature Medicine·Christopher A KlebanoffNicholas P Restifo
Feb 26, 2016·Science Translational Medicine·Bernhard MlecnikJérôme Galon
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 21, 2016·Computational and Structural Biotechnology Journal·Marco Ruella, Marcela V Maus
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Ludmila DanilovaJanis M Taube
Mar 23, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J H LeeH Rizos
Mar 31, 2017·Journal of Hematology & Oncology·Shengnan YuKongming Wu
Apr 25, 2017·Journal of Hematology & Oncology·Tala Achkar, Ahmad A Tarhini

❮ Previous
Next ❯

Citations

Jan 12, 2019·Journal for Immunotherapy of Cancer·Claudia MaletzkiChristian Junghanss
Jan 1, 2018·Current Anesthesiology Reports·Tayab AndrabiMuzaffar H Qazilbash
Jan 20, 2022·Journal of Biomedical Materials Research. Part a·Edson J ComparettiValtencir Zucolotto

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM-CSF

Methods Mentioned

BETA
xenograft
RNAseq

Clinical Trials Mentioned

NCT03203005
NCT02817633
NCT02913313
NCT03341143
NCT02453282
NCT02125461
NCT02578680
NCT02477826
NCT02576509
NCT02702401

Software Mentioned

DisHet

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.